Genomic Activation of <i>PPARG</i> Reveals a Candidate Therapeutic Axis in Bladder Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28923856.
- Also identified by DOI 10.1158/0008-5472.CAN-17-1701 and PMC identifier 5835321.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The <i>PPARG</i> gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the <i>RXRA</i> gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of <i>PPARG</i> or <i>RXRA</i> lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. <i>Cancer Res; 77(24); 6987-98. ©2017 AACR</i>.
Medical subject headings
- Molecular Targeted Therapy
- PPAR gamma
- Urinary Bladder Neoplasms